A randomized phase 2 study of an individualized neoantigen-targeting immunotherapy in patients with newly diagnosed metastatic microsatellite stable colorectal cancer (MSS-CRC).
Joel Randolph Hecht, Alexander I. Spira, Anthony V. Nguyen, Lyudmyla Derby Berim, Alexander Starodub, Meredith S. Pelster, David H. Gallinson, Anup Kasi, Matthew J. Reilley, Agustin Pimentel, Ki Young Chung, Fa-Chyi Lee, Brian A. Chauder, Kyounghwa Bae, Desiree Schneck, Andrew R. Allen, Karin U. Jooss, Andrew R. Ferguson, Joseph Thaddeus Beck
The abstract is not reproduced here because its license does not permit redistribution. Read it at the original source.
Record
- Archive ID
- doi:10.1200/jco.2025.43.4_suppl.lba13
- Published
- Jan 27, 2025
- Venue
- Journal of Clinical Oncology
- DOI
- 10.1200/jco.2025.43.4_suppl.lba13
- Categories
- Cancer Immunotherapy and Biomarkers
- Provenance
- openalex